Novel strategy for the use of leptin for obesity therapy
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Obesity is a chronic disease and a major global health challenge. Apart from bariatric surgery, which is costly and not without risk, there are currently no successful long-term treatment options for obesity. The history of pharmacological agents for obesity has been turbulent with many examples of drugs being removed from the market due to significant side effects. Orlistat and sibutramine (the latest drugs on the market) provide only modest weight loss and are both associated with high attrition rates due to intolerable side effects. Furthermore, sibutramine was recently withdrawn from the market. There is a need for the development of safe and efficacious drug treatments for obesity. AREAS COVERED: This review covers the history of leptin therapy as an orphan drug, leptin-replacement therapy as a treatment for obesity, preclinical studies showing the efficacy of leptin/amylin combination and finally, the very promising early clinical findings using pramlintide/meteleptin combination therapy in overweight to obese individuals. EXPERT OPINION: Combination pharmacological therapy, such as pramlintide/metreleptin, for the treatment of obesity is very promising and is supported by encouraging weight loss results and improvement in metabolic makers in early-phase clinical studies. However, the latest randomized clinical trial on pramlintide/metreleptin was recently stopped due to safety concerns.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053 · cited 1×
“Stimulation of fatty acid oxidation throughout the body and lowering of plasma, hepatic and myocellular lipid levels resulting in increased insulin sensitivity and improved glycemic control [53-60] .”
BackgroundChanges in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 1×
“This response is characterized by a drop in energy expenditure beyond that predicted by changes in body composition [27-28], blunted neuroendocrine functions (the thyroid and reproductive axes are suppressed, there is decreased sympathetic activity and increased parasympathetic activity) and circulating leptin levels…”
BackgroundEffects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998 · cited 3×
“Pivotal trial(s) Type 1 diabetes: [65-67] Type 2 diabetes: [68-70] Congenital leptin deficiency [18] Lipodystrophy: [20] Hypothalamic amenorrhea: [22] Obesity: [26,47] Weight maintenance: [37] Pramlintide acetate & metreleptin”
BackgroundFrederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Heymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA · doi:10.1001/jama.282.16.1568 · Cited by 1,422
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247 · cited 4×
“Improvement in insulin suppression of glucose production in the liver and increase in insulin-stimulated peripheral glucose uptake in the muscle [20,53,61] Therefore, leptin acts via multiple mechanisms to decrease triglyceride and other lipid intermediates in lipodystrophy patients, reducing their accumulation in tis…”
BackgroundInfluentialFarooqi, I. S., Matarese, G., Lord, G. M., Keogh, J. M., Lawrence, E., Agwu, C., Sanna, V., Jebb, S. A., Perna, F., Fontana, S., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215693 · Cited by 1,105
Pi-Sunyer, X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2074 · Cited by 1,025
Recombinant human leptin in women with hypothalamic amenorrhea
Welt, C. K., Chan, J. L., Bullen, J., Murphy, R., Smith, P., DePaoli, A. M., Karalis, A., & Mantzoros, C. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040388 · Cited by 908
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215001 · Cited by 800 · cited 2×
“Improvement in insulin suppression of glucose production in the liver and increase in insulin-stimulated peripheral glucose uptake in the muscle [20,53,61] Therefore, leptin acts via multiple mechanisms to decrease triglyceride and other lipid intermediates in lipodystrophy patients, reducing their accumulation in tis…”
BackgroundRegion-Specific Leptin Resistance within the Hypothalamus of Diet-Induced Obese Mice
Münzberg, H., Flier, J. S., & Bjørbæk, C. (2004) · Endocrinology · doi:10.1210/en.2004-0726 · Cited by 737 · cited 1×
“As described above, obesity-related leptin resistance appears to be caused by defects in leptin action in the hypothalamus [40,41].”
BackgroundRosenbaum, M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25977 · Cited by 575 · cited 3×
“After five weeks of daily recombinant leptin treatment, subjects not only restored their baseline leptin levels, but also reversed this metabolic phenotype and returned to baseline values [37,38].”
BackgroundRoth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436
Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307
Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307
Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264 · cited 1×
“Pivotal trial(s) Type 1 diabetes: [65-67] Type 2 diabetes: [68-70] Congenital leptin deficiency [18] Lipodystrophy: [20] Hypothalamic amenorrhea: [22] Obesity: [26,47] Weight maintenance: [37] Pramlintide acetate & metreleptin”
Rapid transformation of white adipocytes into fat-oxidizing machines
Orci, L., Cook, W. S., Ravazzola, M., Wang, M.-Y., Park, B.-H., Montesano, R., & Unger, R. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308258100 · Cited by 234 · cited 1×
“Stimulation of fatty acid oxidation throughout the body and lowering of plasma, hepatic and myocellular lipid levels resulting in increased insulin sensitivity and improved glycemic control [53-60] .”
BackgroundLeptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy†
Javor, E. D., Ghany, M. G., Cochran, E. K., Oral, E. A., DePaoli, A. M., Premkumar, A., Kleiner, D. E., & Gorden, P. (2005) · Hepatology · doi:10.1002/hep.20672 · Cited by 228 · cited 2×
“, induced by chronic energy deficiency) would support the hypothesis of central leptin sensitivity restoration [21,22].”
BackgroundLong-Term Efficacy of Leptin Replacement in Patients With Generalized Lipodystrophy
Javor, E. D., Cochran, E. K., Musso, C., Young, J. R., DePaoli, A. M., & Gorden, P. (2005) · Diabetes · doi:10.2337/diabetes.54.7.1994 · Cited by 226 · cited 1×
“Stimulation of fatty acid oxidation throughout the body and lowering of plasma, hepatic and myocellular lipid levels resulting in increased insulin sensitivity and improved glycemic control [53-60] .”
BackgroundPPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue
Lee, Y., Yu, X., Gonzales, F., Mangelsdorf, D. J., Wang, M.-Y., Richardson, C., Witters, L. A., & Unger, R. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182420899 · Cited by 181
Edelman, S., Garg, S., Frias, J., Maggs, D., Wang, Y., Zhang, B., Strobel, S., Lutz, K., & Kolterman, O. (2006) · Diabetes Care · doi:10.2337/dc06-0042 · Cited by 166
Moon, H.-S., Matarese, G., Brennan, A. M., Chamberland, J. P., Liu, X., Fiorenza, C. G., Mylvaganam, G. H., Abanni, L., Carbone, F., Williams, C. J., et al. (2011) · Diabetes · doi:10.2337/db10-1791 · Cited by 151 · cited 5×
“In these tissues, multiple cellular pathways such as the ras-related C3 botulinum toxin substrate-alpha serine/threonine-protein kinase (AKT), AMPK and extracellular signal-regulated kinase (ERK) pathways were induced by either or both of the molecules, suggesting some of the mechanisms by which beneficial effects of…”
BackgroundInfluentialMcDuffie, J. R., Riggs, P. A., Calis, K. A., Freedman, R. J., Oral, E. A., DePaoli, A. M., & Yanovski, J. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031868 · Cited by 129 · cited 1×
“Correction of hyperphagia secondary to leptin deficiency and the concomitant reduction in caloric and fat intake [51,52] .”
BackgroundRiddle, M., Frias, J., Zhang, B., Maier, H., Brown, C., Lutz, K., & Kolterman, O. (2007) · Diabetes Care · doi:10.2337/dc07-0589 · Cited by 116
Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy
Moran, S. A., Patten, N., Young, J. R., Cochran, E., Sebring, N., Reynolds, J., Premkumar, A., Depaoli, A. M., Skarulis, M. C., Oral, E. A., et al. (2004) · Metabolism · doi:10.1016/j.metabol.2003.10.019 · Cited by 96 · cited 1×
“Correction of hyperphagia secondary to leptin deficiency and the concomitant reduction in caloric and fat intake [51,52] .”
BackgroundRiddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., & Porter, L. (2009) · Diabetes Care · doi:10.2337/dc09-0395 · Cited by 66
Cited by
Leptin applications in 2015: what have we learned about leptin and obesity?
Farr, O. M., Gavrieli, A., & Mantzoros, C. S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000184 · Cited by 233
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“Pramlintide/metreleptin combination therapy showed promising effects on weight loss, but the trial was halted due to safety concerns.(221) NPY is an incretin hormone that plays a critical role in the physiologic control of appetite, satiety, and energy homeostasis and stimulates food intake, reduces energy expenditure…”
Background
Metadata
- Authors
- Tam, C. S., Lecoultre, V., & Ravussin, E.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2011-09-13
- Volume
- 11
- Issue
- 12
- Pages
- 1677-1685
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W1999276645
- Cited by
- 43
- References
- 26
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.